<DOC>
	<DOC>NCT02083107</DOC>
	<brief_summary>The aim of the work is to evaluate &amp; compare the effectiveness of rectally administered PGE1 synthetic analogue (misoprostol) 400 microgram versus sublingually administered misoprostol before caesarean section to decrease blood loss during and after the operation.</brief_summary>
	<brief_title>Comparison Between Rectal &amp; Sublingual Misoprostol Before Caesarian Section To Reduce Intra &amp; Post-Operative Blood Loss</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Postpartum Hemorrhage</mesh_term>
	<mesh_term>Postoperative Hemorrhage</mesh_term>
	<mesh_term>Misoprostol</mesh_term>
	<criteria>1. Patients booked for elective cesarean section. 2. Singleton pregnancies. 3 Full term pregnancies (GA 3742 weeks). 4 Patients with only previous one cesarian section 1. Primigravida. 2. Blood dyscrasias. 3. Large fibroids. 4. Multiple pregnancies. 5. Overdistended uterus eg. Hydramnios. 6. Preeclampsia. 7. Marked maternal anemia (Preoperative hemoglobin &lt; 9 gm/dl). 8. Previous history of PPH. 9. Contraindications to prostaglandin therapy (e.g. history of severe bronchial asthma or allergy to misoprostol. 10. Placenta previa. 11. Contraindication to spinal anesthesia. 12. Previous myomectomy. 13. Previous two or more C.S.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Postpartum hemorrhage</keyword>
	<keyword>Intrapartum blood loss</keyword>
	<keyword>Misoprostol</keyword>
</DOC>